A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Recruiting

Phase 3

EfgartigimodA Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

Sponsor:

argenx

Code:

NCT07570316

Conditions

Graves' Disease

Graves Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Efgartigimod PH20 SC

Placebo PH20 SC

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-19. This information was provided to ClinicalTrials.gov by argenx on 2026-07-08.